2ND ANNUAL PHARMACEUTICAL COMPETITIVENESS CONFERENCE TO TAKE PLACE IN YEREVAN

armradio.am
27.11.2009 18:08

The USAID-funded Competitive Armenian Private Sector (CAPS) Project
in partnership with the Ministry of Health, the Scientific Center
of Drug and Medical Technology Expertise, the Union of Medicine
Producers and Importers of Armenia, Armenian Development Agency, and
National Competitiveness Foundation are organizing the 2rd Armenian
Pharmaceutical Competitiveness Conference on December 1 in Yerevan.

The event aims to update industry representatives on the current status
of the sector, promote collaboration among pharmaceutical sector
stakeholders, and encourage discussions on major industry issues,
including financial crisis impact on pharmaceutical production,
adoption of Good "X" Practices (GXP) regulations and export market
opportunities.

The conference builds upon the success of the first Pharmaceutical
Competitiveness Conference, held last November by CAPS and its
major partners in the pharmaceutical industry. The conference
focused on introducing Good Manufacturing Practices (GMP). Since
then, notable steps have been taken toward GMP implementation in
Armenia. For example, in May this year, a GMP training program
featuring international experts was conducted in Armenia for the
first time through the joint efforts of the CAPS Project and major
industry stakeholders. The GMP training was followed by a trainers’
course, creating local GMP trainers able to continue pharmaceutical
training through the GXP Center of Excellence, which was established
in June this year.

Conference participants will discuss opportunities for Armenian
pharmaceutical producers in domestic and foreign markets, the need for
improvements in medicine regulation, as well as the current situation
of medicine production in Armenia and possible development scenarios.

The event is open to pharmaceutical producers, government and
international organizations, educational institutions, NGOs, business
associations, pharmaceutical professionals, the press and those
interested in Armenia’s pharmaceutical industry.